BIAF (bioAffinity Technologies) Short Ratio


BIAF bioAffinity Technologies Inc BIAF
44 GF Score
Price $0.76
GF Value $4.26
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is bioAffinity Technologies Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BIAF
44GF Score
bioAffinity Technologies Inc BIAF
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is bioAffinity Technologies (BIAF) Overvalued in 2026?

Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued. The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.26. GuruFocus considers bioAffinity Technologies to be Possible Value Trap.

Key valuation signals for BIAF:

  • Short Ratio:
  • GF Value™: $4.26 vs. price of $0.76 (82.2% below fair value)
  • GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

bioAffinity Technologies Business Description

Address 3300 Nacogdoches Road, Suite 216, San Antonio, TX, USA, 78217
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score

Get the complete analysis for BIAF

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price
$4.26
GF Value